Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough

Group 1 - Summit Therapeutics (NASDAQ:SMMT) is identified as one of the 17 biotechnology stocks with more than 50% upside potential, with a projected median 1-year price target of $57.98, indicating a strong upside of over 296% [1] - The U.S. FDA has accepted Summit Therapeutics' application for ivonescimab, a lung cancer treatment, with a decision date set for November 14, 2026, based on data from the global phase III HARMONi trial [2][4] - The application targets a market gap for approximately 14,000 eligible U.S. patients annually and is supported by a partnership with Akeso for commercial exposure in China, positioning the company for potential entry into the U.S. oncology market [3] Group 2 - Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing ivonescimab, a bispecific antibody that combines PD-1 blockade and anti-angiogenesis in a single molecule, and is currently conducting Phase III clinical trials for non-small cell lung cancer [4]